[ad_1]
Based on analysis agency Pharmarack, the market has tripled in two years after witnessing a sluggish progress until 2021. Over the past 5 years, the market has grown at 32% CAGR to 474 crore in January 2024.
Based on the information by Pharmarack, semaglutide has round 66% of the worth market share within the anti-obesity phase.
The chubby prevalence price within the nation in the present day is near 22% for the primary inhabitants 23% for the feminine inhabitants and near 11% youngsters. Sheetal Sapale, VP industrial, Pharmarack, mentioned: “One in 4 adults falls within the chubby class. Nearly 5% of Indian inhabitants of 1.4 billion falls within the morbidly overweight class. These statistics point out that as India grows to turn out to be a superpower, it is usually adapting illness patterns of nations on this bracket,” she mentioned.
The oral semaglutide pill, branded Rybelsus, which was permitted for remedy of diabetes, was launched in India in January 2022. However the drug can also be prescribed for weight discount. Since then, the anti-obesity drug market has seen a pointy improve from ₹174 crore to ₹474 crore in January this yr.
Docs vouch for the drug however there’s a rider.”Largely they’re good, scale back weight and profit folks with coronary heart drawback, kidney drawback and points with the liver. Nevertheless, sufferers shouldn’t begin taking the drug on their very own. It’s not like paracetamol, due to this fact, physician’s prescription is a should,” mentioned Dr Anoop Misra, chairman of Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Ailments and Endocrinology.Sapale mentioned nearly 11% of kids are chubby, indicating bigger inhabitants uncovered to weight-related issues in future. Many anti-obesity medication have entered the market in the present day.
(Now you can subscribe to our Financial Occasions WhatsApp channel)
[ad_2]
Source link
